Mr. Rob Fia reports

THERMA BRIGHT SELLS AN ADDITIONAL 200-UNITS OF VENOWAVE(TM) TO STRATEGIC DISTRIBUTION PARTNER GEN-X MED

Therma Bright Inc. has received a follow-on order for an additional 200 Venowave VW5 units from its Texas-based distribution partner, Gen-X Med.

This latest transaction marks the expansion of the relationship between the two companies following the successful initial integration of the Venowave system into Gen-X Med's specialized health care network. The units are destined for use by top-tier orthopedic surgeons, specifically targeting postsurgical recovery for specialized knee procedures -- a high-growth segment in the U.S. health care landscape.

Rob Fia, chief executive officer, commented: "The speed at which Gen-X Med has returned for additional inventory speaks volumes about the clinical demand for the Venowave VW5. This second 200-unit order reinforces our belief that the market is hungry for mobile, effective and reimbursable compression solutions. By helping surgeons reduce postoperative complications and hospital readmissions, we are not only improving patient lives but also providing a clear economic benefit to the U.S. health care system. We look forward to scaling this volume as Gen-X Med continues to educate their expansive doctor network."

Beau Wood, president of Gen-X Med, commented: "Our initial rollout confirmed what we suspected: Patients and providers prefer the mobility and efficacy of the Venowave over traditional, tethered compression devices. Securing these additional 200 units allows us to keep pace with the growing adoption rate among our specialized knee surgeons. We are seeing a shift toward at-home recovery solutions, and Venowave is the clear leader in that transition."

The growing compression therapy market

The global compression therapy market is currently experiencing significant tailwinds. According to industry data from Straits Research, the market was valued at $4.18-billion in 2024 and is projected to reach $6.72-billion by 2033, growing at a steady compound annual growth rate (CAGR) of 7.30 per cent. This growth is driven by an aging population, an increase in orthopedic surgeries, and a heightened focus on preventing deep vein thrombosis (DVT) and other circulatory disorders.

About the Venowave VW5

The Venowave VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the FDA-designated (U.S. Food and Drug Administration) durable medical equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lymphatic function. Clinically shown to enhance venous blood flow by 64 per cent after just two minutes of use and 88 per cent after 50 minutes, the Venowave is the only Medicare-approved reimbursable mobile mechanical compression system available in the United States under its HCPCS (Healthcare Common Procedure Coding System) code E0683. It provides a comfortable and simple treatment solution to accelerate postoperative recovery while managing pain and swelling.

About Therma Bright Inc.

Therma Bright is a developer and investment partner specializing in advanced diagnostic and medical device technologies. The company's portfolio includes innovative solutions for vascular health, respiratory diagnostics and topical treatments. Therma Bright is listed on the TSX Venture Exchange (symbol: THRM), the OTCQB (symbol: TBRIF) and the Frankfurt Stock Exchange (symbol: JNX0).

We seek Safe Harbor.